| pubmed-article:16844422 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16844422 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:16844422 | lifeskim:mentions | umls-concept:C0030922 | lld:lifeskim |
| pubmed-article:16844422 | lifeskim:mentions | umls-concept:C0358591 | lld:lifeskim |
| pubmed-article:16844422 | lifeskim:mentions | umls-concept:C0348016 | lld:lifeskim |
| pubmed-article:16844422 | lifeskim:mentions | umls-concept:C0006347 | lld:lifeskim |
| pubmed-article:16844422 | lifeskim:mentions | umls-concept:C0010181 | lld:lifeskim |
| pubmed-article:16844422 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:16844422 | pubmed:dateCreated | 2006-8-1 | lld:pubmed |
| pubmed-article:16844422 | pubmed:abstractText | The most cost-effective route of administering proton pump inhibitor (PPI) therapy in peptic ulcer hemorrhage remains uncertain. Oral (PO) PPI therapy may be less effective than intravenous (IV) PPI therapy, but is less expensive and does not mandate a 72-hour posthemostasis hospital stay to complete a full therapeutic course. Because there are currently no published head-to-head clinical trials comparing IV vs PO PPIs, we used decision analysis with budget impact modeling to measure the clinical and economic outcomes of these competing modes of administration. | lld:pubmed |
| pubmed-article:16844422 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16844422 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16844422 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16844422 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16844422 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16844422 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16844422 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16844422 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:16844422 | pubmed:issn | 1542-3565 | lld:pubmed |
| pubmed-article:16844422 | pubmed:author | pubmed-author:GralnekIan... | lld:pubmed |
| pubmed-article:16844422 | pubmed:author | pubmed-author:DulaiGareth... | lld:pubmed |
| pubmed-article:16844422 | pubmed:author | pubmed-author:SpiegelBrenna... | lld:pubmed |
| pubmed-article:16844422 | pubmed:author | pubmed-author:KanwalFasihaF | lld:pubmed |
| pubmed-article:16844422 | pubmed:author | pubmed-author:LimBrian SBS | lld:pubmed |
| pubmed-article:16844422 | pubmed:author | pubmed-author:MannNeelN | lld:pubmed |
| pubmed-article:16844422 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16844422 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:16844422 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16844422 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16844422 | pubmed:pagination | 988-997 | lld:pubmed |
| pubmed-article:16844422 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:16844422 | pubmed:meshHeading | pubmed-meshheading:16844422... | lld:pubmed |
| pubmed-article:16844422 | pubmed:meshHeading | pubmed-meshheading:16844422... | lld:pubmed |
| pubmed-article:16844422 | pubmed:meshHeading | pubmed-meshheading:16844422... | lld:pubmed |
| pubmed-article:16844422 | pubmed:meshHeading | pubmed-meshheading:16844422... | lld:pubmed |
| pubmed-article:16844422 | pubmed:meshHeading | pubmed-meshheading:16844422... | lld:pubmed |
| pubmed-article:16844422 | pubmed:meshHeading | pubmed-meshheading:16844422... | lld:pubmed |
| pubmed-article:16844422 | pubmed:meshHeading | pubmed-meshheading:16844422... | lld:pubmed |
| pubmed-article:16844422 | pubmed:meshHeading | pubmed-meshheading:16844422... | lld:pubmed |
| pubmed-article:16844422 | pubmed:meshHeading | pubmed-meshheading:16844422... | lld:pubmed |
| pubmed-article:16844422 | pubmed:meshHeading | pubmed-meshheading:16844422... | lld:pubmed |
| pubmed-article:16844422 | pubmed:meshHeading | pubmed-meshheading:16844422... | lld:pubmed |
| pubmed-article:16844422 | pubmed:meshHeading | pubmed-meshheading:16844422... | lld:pubmed |
| pubmed-article:16844422 | pubmed:meshHeading | pubmed-meshheading:16844422... | lld:pubmed |
| pubmed-article:16844422 | pubmed:meshHeading | pubmed-meshheading:16844422... | lld:pubmed |
| pubmed-article:16844422 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16844422 | pubmed:articleTitle | The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage. | lld:pubmed |
| pubmed-article:16844422 | pubmed:affiliation | Division of Gastroenterology, Veteran's Administration Greater Los Angeles Healthcare System, California, USA. | lld:pubmed |
| pubmed-article:16844422 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16844422 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:16844422 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16844422 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16844422 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16844422 | lld:pubmed |
